

INSTITUTIONAL BIOSAFETY COMMITTEE REVIEW

MEETING MINUTES

Meeting Date: Tuesday, February 17, 2026
Time: 11:00 am Eastern Time
Location: Zoom Teleconference
Institution: Northside Hospital, Atlanta, GA
Principal Investigator: Scott R. Solomon, MD
Protocol: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company, CA0881005
NCT Number: NCT06121843
Meeting Type: Continuing Review of Protocol and Site
Title: A Phase 1, Multicenter, Open-label Study to Evaluate the Safety and Preliminary Efficacy of BMS-986393 in Novel Combinations in Participants with Relapsed and/or Refractory Multiple Myeloma and Determine the Recommended Dose for Each Add-on Investigational Component

1. Call to order:

The Meeting was called to order at 11:18 am Eastern Time.

2. Introductions and orientation:

Introductions were made and the Chair oriented members to the meeting procedures.

3. Declaration of quorum:

Four voting members were present, including two local members unaffiliated with the institution. Also present were two Institutional Representatives and IBC Services staff. The Chair declared that a quorum was present.

4. Conflict of Interest:

The Chair requested that voting members report any conflict of interest regarding this meeting. No conflicts of interest were reported.

5. Public posting:

An Institutional Representative confirmed that notice of the meeting was publicly posted. No public comments were received by the site or the Committee regarding this review.

6. Approval of previous meeting minutes:

Minutes Approved - YES: 4 NO: 0 ABSTAIN: 0

7. Review of proposed research:

The Chair provided an overview of the protocol and status of the study.

The Chair noted changes since the last review.

Point of Discussion:

1. The Committee noted that cells of the tongue may express GPRC5D and that CC-95266 could be present in the oral cavity which could theoretically increase the risk of transmission of the study agent to others. The Committee noted that while this is a theoretical possibility, the risk of an exposure is extremely unlikely and the number of CC-95266 cells would be very low, which if transferred to another individual would likely not survive for very long.

8. Determination for biosafety level and period of IBC oversight:

The Committee previously determined that **BSL-2 containment facilities and practices** are required for CC-95266, since it consists of primary human cells modified using a recombinant lentiviral vector. The Committee reaffirmed this determination.

The Committee previously determined that IBC oversight will continue for **3 months after the last subject's last dose of CC-95266 locally**, provided all other criteria for study closure are met. The Committee reaffirmed this determination.

INSTITUTIONAL BIOSAFETY COMMITTEE REVIEW

9. Vote on the Protocol:

The Committee voted for the following determination on the Protocol:

X	APPROVED
	CONDITIONALLY APPROVED
	TABLED
	DISAPPROVED

DETERMINATION VOTE - YES: 4 NO: 0 ABSTAIN: 0

10. Review of proposed facilities and practices:

The Chair provided an overview of the arrangement for the facilities and practices.

Points of Discussion:

1. The Committee noted that a new Site Inspection Checklist Autoclave Addendum is due to be completed prior to the end of March 2026.
2. The Committee recommended that the second line of personal protective equipment (PPE) listed on the Biohazard Sign be revised to read as, "Use the following PPE for handling at all other times and for spill clean-up: gloves, gown, mask and eye protection".
3. An Institutional Representative noted that full containers of biohazardous waste generated in the Pharmacy is kept within the HSC Laboratory under a counter where it is picked up directly two times per week by the commercial biohazardous waste hauler. The Committee determined that this is acceptable.
4. The Committee recommended that the Site Map be revised to note where in the HSC Laboratory the biohazardous waste container is stored and that a photo of this area be submitted to IBC Services.

11. Site requirements:

The Chair reviewed training and communication requirements for maintaining IBC approval with the Institutional Representatives.

12. Vote on the Site:

The Committee voted for the following determination on the Site:

X	APPROVED
	CONDITIONALLY APPROVED
	TABLED
	DISAPPROVED

DETERMINATION VOTE - YES: 4 NO: 0 ABSTAIN: 0

13. Advice to the Institution: None.

14. Meeting adjourned: The meeting was adjourned at 11:25 am Eastern Time.

15. Post-meeting notes: None.

Documents reviewed:

Agenda

Protocol, Amendment 03, dated 12-23-2025

Investigator's Brochure, Version 05, dated 10-01-2025

Pharmacy Manual, Version 3.0, dated 08-21-2025

Global Product Administration Manual, Version 1.0, dated 10-31-2025

Research Modification Evaluation, Protocol, Amendment 02

Research Modification Evaluation, Protocol, Amendment 03

Research Modification Evaluation, Investigator's Brochure, Version 05

Research Modification Evaluation, Pharmacy Manual, Version 2.0

Research Modification Evaluation, Pharmacy Manual, Version 2.1

Research Modification Evaluation, Pharmacy Manual, Version 3.0

Biological Risk Assessment and Summary, updated 01-20-2026

Site Map, BMT Unit, 4th Floor, dated 01-29-2024

Site Map, HSC Laboratory, dated 01-29-2024

Site Inspection Checklist, GMHC, expires 01-29-2028

Photos, HSC Lab, BMT Unit, dated 07-03-2025

INSTITUTIONAL BIOSAFETY COMMITTEE REVIEW

Biohazard Sign, Genetically Modified Human Cells, dated 01-26-2026
Biological Safety Cabinet Certifications, HSC Lab, expire 06-2026
SOP, Biosafety for Genetically Modified Human Cells, dated 01-26-2026
SOP Addendum, Biosafety for Autologous Cells, dated 01-26-2026
Training, Shipping Certifications, expire 03-10-2026, 04-30-2026
CRRF, dated 11-03-2025
Prior Meeting Minutes, Continuing, dated 02-21-2025